Pfizer Employs Pricing Ploy
FDA Gives Nod to Protalix's Elelyso in Gaucher Disease
Last week, the FDA increased the options available in Type I Gaucher disease by approving Elelyso (taliglucerase alfa), a recombinant version of the hydrolytic human lysosomal enzyme glucocerebrosidase. The compound was discovered by Protalix BioTherapeutics Inc., which is partnered with Pfizer Inc. on development and commercialization outside Israel.
To continue reading subscribe now to BioWorld Asia (formerly International)
Learn More about BioWorld Asia (formerly International)
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.